{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:01:51Z","timestamp":1790359311231,"version":"4.1.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012456","name":"the National Social Science Fund of China","doi-asserted-by":"publisher","award":["22BGL223"],"award-info":[{"award-number":["22BGL223"]}],"id":[{"id":"10.13039\/501100012456","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Whether abnormal returns around different pharmaceutical policy events exhibit similar patterns, and whether these patterns vary across industry-index levels, return scales, and event windows, has received limited comparative examination within a unified analytical framework. This study examines six pharmaceutical policy events in China using the Shenwan first-level Pharmaceutical and Biotechnology Index and six Shenwan second-level pharmaceutical sub-sector indices, with the CSI 300 Index as the market benchmark. Ensemble Empirical Mode Decomposition (EEMD) is used to reconstruct returns at multiple scales, and an event-study framework is applied to estimate abnormal returns (ARs) and cumulative abnormal returns (CARs). The results show that, within the events, industry indices, and event windows examined, policy objectives or policy-instrument attributes do not exhibit a consistent correspondence with observed abnormal-return patterns. Medium-frequency CARs were generally negative for both centralized procurement events, but centralized drug procurement showed broader negative accumulation across sub-sectors, whereas centralized procurement of high-value medical consumables showed greater sectoral differentiation. Although the clinical trial data self-inspection and verification event and the reform of the drug review and approval system both involved drug R&amp;D and registration regulation, their abnormal-return patterns differed markedly, with the latter showing broadly positive medium-frequency CARs. The aggregate industry index may not fully capture underlying differences when sub-sector responses diverge substantially, and high- and medium-frequency CARs also differ in direction for some events and sub-sectors. In addition, the cumulative direction of CARs over wider event windows may differ from the trajectory of daily ARs following the policy announcement. Overall, generalizations based on policy categories, an aggregate industry index, or a single event window may overlook important differences in abnormal returns across industry-index levels, return scales, and temporal paths.<\/jats:p>","DOI":"10.1371\/journal.pone.0353989","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:47:53Z","timestamp":1790358473000},"page":"e0353989","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneous stock market responses to pharmaceutical policy events across subsectors and time scales: Evidence from China"],"prefix":"10.1371","volume":"21","author":[{"given":"Xiangfei","family":"Li","sequence":"first","affiliation":[{"name":"School of Economics and Management, Tiangong University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1701-9993","authenticated-orcid":true,"given":"Yidan","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Economics and Management, Tiangong University","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"2","key":"pone.0353989.ref001","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2307\/2325486","article-title":"Efficient capital markets: a review of theory and empirical work","volume":"25","author":"EF Fama","year":"1970","journal-title":"J Finance"},{"issue":"4","key":"pone.0353989.ref002","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1093\/qje\/qjw024","article-title":"Measuring economic policy uncertainty","volume":"131","author":"SR Baker","year":"2016","journal-title":"Q J Econ"},{"issue":"5","key":"pone.0353989.ref003","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/acfi.12338","article-title":"Economic policy uncertainty in China and stock market expected returns","volume":"57","author":"J Chen","year":"2017","journal-title":"Account Finance"},{"issue":"1","key":"pone.0353989.ref004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0304-405X(85)90042-X","article-title":"Using daily stock returns: The case of event studies","volume":"14","author":"SJ Brown","year":"1985","journal-title":"J Financ Econ"},{"key":"pone.0353989.ref005","first-page":"3","article-title":"Econometrics of event studies.","author":"SP Kothari","year":"2007","journal-title":"Eckbo BE, editor. Handbook of empirical corporate finance"},{"issue":"6","key":"pone.0353989.ref006","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1111\/0022-1082.00184","article-title":"A unified theory of underreaction, momentum trading, and overreaction in asset markets","volume":"54","author":"H Hong","year":"1999","journal-title":"J Finance"},{"key":"pone.0353989.ref007","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pacfin.2014.06.002","article-title":"Investor attention, information diffusion and industry returns","volume":"30","author":"Q Wu","year":"2014","journal-title":"Pacific-Basin Finance Journal"},{"issue":"8","key":"pone.0353989.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071966","article-title":"Stock market returns and clinical trial results of investigational compounds: an event study analysis of large biopharmaceutical companies","volume":"8","author":"TJ Hwang","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"pone.0353989.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272851","article-title":"The reaction of sponsor stock prices to clinical trial outcomes: an event study analysis","volume":"17","author":"M Singh","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"pone.0353989.ref010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.qref.2005.01.003","article-title":"Market response to FDA announcements","volume":"46","author":"SK Sarkar","year":"2006","journal-title":"Quart Rev Econ Finance"},{"issue":"1","key":"pone.0353989.ref011","article-title":"How does news affect biopharma stock prices?: an event study","volume":"19","author":"J Cho","year":"2024","journal-title":"PLoS One"},{"issue":"18","key":"pone.0353989.ref012","doi-asserted-by":"crossref","first-page":"11730","DOI":"10.3390\/ijerph191811730","article-title":"The impact of medical and health fiscal expenditures on pharmaceutical industry stock index in China","volume":"19","author":"C Su","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"22","key":"pone.0353989.ref013","doi-asserted-by":"crossref","first-page":"12037","DOI":"10.3390\/ijerph182212037","article-title":"Will the volume-based procurement policy promote pharmaceutical firms\u2019 R&D investment in China? An event study approach","volume":"18","author":"Y Hu","year":"2021","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"pone.0353989.ref014","article-title":"The impact of the centralized volume-based procurement policy on Chinese pharmaceutical manufacturing firms\u2019 R&D investment: a difference-in-differences approach","volume":"20","author":"F Qiu","year":"2025","journal-title":"PLoS One"},{"key":"pone.0353989.ref015","doi-asserted-by":"crossref","first-page":"1192423","DOI":"10.3389\/fphar.2023.1192423","article-title":"Does China\u2019s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model","volume":"14","author":"Y Gu","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0353989.ref016","doi-asserted-by":"crossref","first-page":"1227102","DOI":"10.3389\/fpubh.2023.1227102","article-title":"Impact of China\u2019s national centralized drug procurement policy on pharmaceutical enterprises\u2019 financial performance: a quasi-natural experimental study","volume":"11","author":"Z Sun","year":"2023","journal-title":"Front Public Health"},{"issue":"01","key":"pone.0353989.ref017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1142\/S1793536909000047","article-title":"Ensemble empirical mode decomposition: a noise-assisted data analysis method","volume":"01","author":"Z Wu","year":"2009","journal-title":"Adv Adapt Data Anal"},{"issue":"5","key":"pone.0353989.ref018","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.eneco.2009.04.003","article-title":"Estimating the impact of extreme events on crude oil price: an EMD-based event analysis method","volume":"31","author":"X Zhang","year":"2009","journal-title":"Energy Economics"},{"issue":"2","key":"pone.0353989.ref019","article-title":"Changes in clinical trials of endocrine disorder and metabolism and nutrition disorder drugs in mainland China over 2010-2019","volume":"9","author":"X Liu","year":"2021","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"pone.0353989.ref020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/nsr\/nwz001","article-title":"China\u2019s reform of the regulatory system for medical products and its impact","volume":"6","author":"R Song","year":"2019","journal-title":"Natl Sci Rev"},{"key":"pone.0353989.ref021","doi-asserted-by":"crossref","first-page":"102520","DOI":"10.1016\/j.chieco.2025.102520","article-title":"The impact of National volume-based procurement policy on healthcare expenditure and provider behavior in China","volume":"94","author":"Y Wang","year":"2025","journal-title":"China Economic Review"},{"key":"pone.0353989.ref022","doi-asserted-by":"crossref","first-page":"1585279","DOI":"10.3389\/fpubh.2025.1585279","article-title":"Effects of DRG\/DIP payment reform on hospital pharmacy administration and pharmaceutical services in China: a multicenter cross-sectional study","volume":"13","author":"X Wang","year":"2025","journal-title":"Front Public Health"},{"issue":"2","key":"pone.0353989.ref023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1109\/LSP.2003.821662","article-title":"Empirical mode decomposition as a filter bank","volume":"11","author":"P Flandrin","year":"2004","journal-title":"IEEE Signal Process Lett"},{"key":"pone.0353989.ref024","article-title":"The impact of national centralized drug procurement policy on firm performance: evidence from Chinese pharmaceutical firms","volume":"200","author":"H He","year":"2025","journal-title":"Transp Res E Logist Transp Rev"},{"issue":"10","key":"pone.0353989.ref025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0275773","article-title":"Winners and losers from Pfizer and Biontech\u2019s vaccine announcement: Evidence from S&P 500 (Sub)sector indices","volume":"17","author":"B Kapar","year":"2022","journal-title":"PLoS One"},{"issue":"3","key":"pone.0353989.ref026","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10614-023-10448-6","article-title":"COVID-19 impact on stock markets: a multiscale event analysis perspective","volume":"63","author":"H Li","year":"2024","journal-title":"Comput Econ"},{"issue":"1","key":"pone.0353989.ref027","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0304-405X(88)90025-6","article-title":"Investigating security-price performance in the presence of event-date uncertainty","volume":"22","author":"CA Ball","year":"1988","journal-title":"J Financ Econ"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:48:00Z","timestamp":1790358480000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0353989"}},"subtitle":[],"editor":[{"given":"Ricky Chee Jiun","family":"Chia","sequence":"first","affiliation":[{"name":"Universiti Malaysia Sabah","place":["MALAYSIA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0353989","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]}}}